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MaOBJECTIVES This study sought to demonstrate transcatheter deployment of a circumferential device within
the pericardial space to modify tricuspid annular dimensions interactively and to reduce functional tricuspid regurgitation
(TR) in swine.
BACKGROUND Functional TR is common and is associated with increased morbidity and mortality. There are no
reported transcatheter tricuspid valve repairs. We describe a transcatheter extracardiac tricuspid annuloplasty device
positioned in the pericardial space and delivered by puncture through the right atrial appendage. We demonstrate acute
and chronic feasibility in swine.
METHODS Transatrial intrapericardial tricuspid annuloplasty (TRAIPTA) was performed in 16 Yorkshire swine, including
4 with functional TR. Invasive hemodynamics and cardiac magnetic resonance imaging (MRI) were performed at baseline,
immediately after annuloplasty and at follow-up.
RESULTS Pericardial access via a right atrial appendage puncture was uncomplicated. In 9 naïve animals, tricuspid
septal-lateral and anteroposterior dimensions, the annular area and perimeter, were reduced by 49%, 31%, 59%, and
24% (p < 0.001), respectively. Tricuspid leaﬂet coaptation length was increased by 53% (p < 0.001). Tricuspid geo-
metric changes were maintained after 9.7 days (range, 7 to 14 days). Small effusions (mean, 46 ml) were observed
immediately post-procedure but resolved completely at follow-up. In 4 animals with functional TR, severity of regur-
gitation by intracardiac echocardiography was reduced.
CONCLUSIONS Transatrial intrapericardial tricuspid annuloplasty is a transcatheter extracardiac tricuspid valve
repair performed by exiting the heart from within via a transatrial puncture. The geometry of the tricuspid annulus can
interactively be modiﬁed to reduce severity of functional TR in an animal model. (J Am Coll Cardiol Intv 2015;8:483–91)
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ABBR EV I A T I ON S
AND ACRONYMS
CT = computed tomography
MRI = magnetic resonance
imaging
RAA = right atrial appendage
RV = right ventricular
TR = tricuspid regurgitation
TRAIPTA = transatrial
intrapericardial tricuspid
annuloplasty
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484outcome (4). Isolated tricuspid valve surgery
is associated with high mortality (5,6) and,
therefore, is seldom justiﬁable.
Most clinical TR is “functional” and is
caused by dilation of the right ventricle and
tricuspid annulus (7), resulting from volume
or pressure overload. Less commonly, dila-
tion results from primary right ventricular
(RV) pathology such as RV infarction or
cardiomyopathy. The severity of TR corre-
sponds to tricuspid annulus dimension (8)
and is dependent on individual patient pre-load and afterload conditions, which vary with time.
Surgical annuloplasty restores annular geometry
and improves leaﬂet coaptation (9). Replacement
tricuspid valves are more susceptible to thrombosis
compared with prostheses in the mitral or aortic po-
sitions. Transcatheter repairs have been developed
for functional mitral regurgitation (10–12) but not
functional TR.SEE PAGE 492Transatrial intrapericardial tricuspid annuloplasty
(TRAIPTA) is a novel transcatheter tricuspid valve
repair, guided by x-rayﬂuoroscopy. The pericardium is
accessed via a puncture of the right atrial appendage
(RAA) from within. A circumferential implant, which
exerts compressive force over the tricuspid annulus, is
delivered along the atrioventricular groove within the
pericardial space. Tension on the implant is adjusted
interactively tomodify tricuspid annular geometry and
reduce TR. The RAA puncture is sealed using off-the-
shelf nitinol closure devices.
In this study, we tested pre-clinical feasibility of
transcatheter extracardiac tricuspid annuloplasty in
swine and showed that substantial modiﬁcation of
tricuspid annular geometry is achieved and sustained
for at least 7 days. In animals with induced functional
TR, we showed that TRAIPTA effectively reduces the
severity of tricuspid regurgitation. We also explored
the feasibility of clinical translation through human
cardiac computed tomography (CT) analysis.METHODS
Procedures were approved by the institutional animal
care and use committee. TRAIPTA was performed in
16 Yorkshire swine (mean 48  14 kg) under general
anesthesia and mechanical ventilation. Of these, 9
naïve animals were survived for 7 to 14 days, 4 with
functional TR were survived for up to 48 days and 3
underwent nonsurvival characterization of TRAIPTA
tension and coronary artery protection elements.Hemodynamics and geometry were characterized
at each time point by angiography, magnetic reso-
nance imaging (MRI) at mid-systole at 1.5-T, and/or
320-detector row CT. Selective coronary angiography
was performed before and after TRAIPTA.
TRAIPTA SYSTEM CONFIGURATION. We designed
and built a catheter system comprising a delivery
device and a permanent implant (Figure 1). The
delivery device is formed from an interrupted 0.035-
inch nitinol wire, pre-shaped into a self-expanding
loop to open inside the pericardium and encircle
the heart. The TRAIPTA implant comprises a 2.5-mm
diameter hollow tube of braided 0.005-inch nitinol
wire. The braided design allows the implant to
shorten longitudinally by more than 50%. A braided
polyester suture (Ti-Cron size 2, Covidien, Waltham,
Massachusetts) runs within the hollow implant with
a pre-tied sliding Roeder knot that allows interac-
tive tightening after deployment and that ensures
continuous myocardial apposition. The implant is
pre-mounted on the delivery device loop and is pre-
loaded into a 12-F braided sheath (Cook Medical,
Bloomington, Indiana) for deployment.
TRANSATRIAL PERICARDIAL ACCESS. The RAA was
engaged from the femoral vein with a 4-French
multipurpose catheter (Figure 2) and punctured us-
ing the back end of a 0.035-inch guidewire. The
catheter was exchanged for a 14-F sheath (Cook
Medical); 10 ml of 50% iopamidol/saline was injected
into the pericardial sheath to visualize epicardial
structures (Online Appendix, Online Figure 1).
DELIVERY AND TIGHTENING OF TRAIPTA IMPLANT.
The nitinol loop of the TRAIPTA system opened in-
side the pericardium to encircle the heart along the
atrioventricular groove (Figure 1). The delivery device
was then withdrawn, leaving the TRAIPTA implant in
place. The suture was tightened interactively during
real-time 1.5-T MRI (Aera, Siemens, Erlangen, Ger-
many) to achieve the desired tension.
In animals with functional TR, implant tension
was adjusted during intracardiac echocardiography.
In 2 naïve animals, we assessed the tension-
geometry relationship by applying progressive ten-
sion measured with a force meter, 3 times in each
animal, during real-time MRI.
CLOSURE OF THE RAA PUNCTURE. After TRAIPTA
deployment, pericardial contrast was washed out
and 2 mg/kg triamcinolone was infused to impede
pericardial adhesions (13). Alongside a 0.014-inch
“buddy” guidewire (Ironman, Abbott Vascular, Santa
Clara, California) for emergency bailout, a 5- or 6-mm
nitinol atrial septal occluder (Amplatzer, St. Jude
FIGURE 1 TRAIPTA System and Procedural Steps
(A) Braided suture (packaging and spool), transatrial intrapericardial tricuspid annulo-
plasty (TRAIPTA) implant and delivery device. (B) TRAIPTA implant loaded onto delivery
device. The suture is housed within the hollow TRAIPTA implant with a pre-tied Roeder
sliding knot. (C) The system is advanced into the pericardium through the right atrial
appendage. (D) The nitinol delivery device ensures that the system opens into a loop
inside the pericardium and reaches the atrioventricular groove. (E) The delivery device is
withdrawn. (F) The implant is tightened. See Online Video 1 for demonstration of
TRAIPTA procedure. TRAIPTA ¼ transatrial intrapericardial tricuspid annuloplasty.
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485Medical, St. Paul, Minnesota or Lepu Medical, Bejing,
China) closed the appendage puncture site. A ﬁnal RAA
angiogram conﬁrmed hemostasis before all wires and
sheaths were withdrawn.
ANIMAL MODEL OF FUNCTIONAL TR. Ten naïve York-
shire swine underwent procedures to cause right
ventricular (RV) volume and/or pressure overload
or tricuspid papillary restriction. This included com-
binations of (1) isolated RV infarction by ethanol
infusion into the right coronary artery during balloon
protection of the posterior descending artery (n ¼ 8);
(2) interatrial septostomy with a 20-mm balloon
(n ¼ 4); (3) pulmonary artery infusion of 8 ml of
300- to 700-mm polyvinyl-alcohol spheres to induce
pulmonary hypertension (n ¼ 5); (4) ethanol needle
injection directly into the RV papillary muscles
(n ¼ 1); and (5) stenting open the pulmonary valve to
cause severe regurgitation (n ¼ 1). Of these 10 ani-
mals, 4 were euthanized for intractable ventricular
ﬁbrillation or severe right heart failure after RV
infarction. The remaining 6 developed a dilated right
ventricle, but only 4 of these developed moderate-
severe TR after a mean of 117 days. These 4 animals
underwent TRAIPTA with intracardiac echocardiog-
raphy and were survived for up to 48 days.
HUMAN IMAGING FOR SUITABILITY. We studied human
cardiac CT angiograms of patients with RV enlarge-
ment in the anonymized and delinked National
Heart, Lung, and Blood Institute database. This
does not constitute human subjects research under
US45CFRx46.102(f). Suitability criteria for transatrial
access were the presence of a discrete lobe from
which to puncture and anterior orientation. Patients
were evaluated for the presence of a clearly demar-
cated atrioventricular groove suitable for TRAIPTA.
Epicardial coronary arteries at risk of compression
were identiﬁed.
STATISTICAL ANALYSIS. Data were analyzed using
SPSS 19.0 (IBM, Armonk, New York) and reported
as mean  SD. Differences were examined by 1-way
repeated-measures analysis of variance, with Bon-
ferroni post-hoc tests as appropriate. A p # 0.05 was
considered signiﬁcant.
RESULTS
TRAIPTA was performed in a total of 16 animals
(9 naïve survived for 7 to 14 days, 4 with functional
TR survived up to 48 days, and 3 were not survived
to characterize tension-geometry and coronary pro-
tection elements). Transatrial pericardial access was
successful in a single pass, and the TRAIPTA devicewas consistently delivered to the atrioventricular
groove in 16 of 16 animals. These 2 stages required
<10 min to perform (Online Video 1).
SURVIVAL EXPERIMENTS IN 9 NAÏVE ANIMALS.
Signiﬁcant tricuspid annular geometric reduction
was achieved by tightening the TRAIPTA implant
(Table 1, Figures 3 and 4), with 49% (p < 0.001)
reduction in the septal-lateral dimension and 31%
(p < 0.001) in the anteroposterior dimension. The
tricuspid annular area and perimeter were reduced
by 59% (p < 0.001) and 24% (p < 0.001), respectively.
FIGURE 2 TRAIPTA Procedure In Vivo
(A) Right atrial appendage (RAA) angiogram. (B) RAA puncture with 0.035-inch guidewire.
(C) A 14-French sheath introduced into the pericardium. (D) The transatrial intrapericardial
tricuspid annuloplasty (TRAIPTA) implant is deployed around the heart within the contrast-
ﬁlled pericardial space. (E) Delivery system (arrows) withdrawal leaving the TRAIPTA
implant in the atrioventricular groove. (F) The TRAIPTA implant is tightened by a sliding
Roeder knot. (G) Closure of the RAA puncture with a nitinol closure device (arrow).
(H) RAA angiogram 7 days later (arrow indicates the closure device).
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486Tricuspid leaﬂet coaptation length (Figure 4) was
signiﬁcantly increased by 53% (p < 0.001). Lesser
mitral annular geometric change was observed with
a mean reduction in the septal-lateral and antero-
posterior dimensions of 15% (p < 0.05) and 15%
(p < 0.05), respectively. No signiﬁcant hemody-
namic changes and no sustained arrhythmias were
observed (Online Table 1). Coronary artery compres-
sion was not seen in any animal (Online Figure 2).
The RAA puncture was consistently closed using a
nitinol closure device in all 9 animals. Post-procedure
MRI demonstrated small pericardial effusions (mean,
46  44 ml), but there was no evidence of tamponade
(Online Table 1). No animal required pericardial
drainage. At follow-up (mean, 9.7 days; range, 7 to
14 days), the TRAIPTA implant remained in place
without migration, and pericardial effusions had
resolved. On necropsy (Figure 5), the implant was
encased in ﬁbrous tissue and fused to the myocar-
dium along its entire course. There were no adhe-
sions between the visceral and parietal pericardial
layers.
SURVIVAL EXPERIMENTS IN 4 ANIMALS WITH
FUNCTIONAL TR. TRAIPTA successfully reduced the
severity of TR by intracardiac echocardiography
(Figure 4). This was maintained up to 48 days of
follow-up. After euthanasia, the TRAIPTA implant
remained intact in the correct anatomic position on
necropsy and was completely endothelialized and
fused to the myocardium (Figure 5).
NONSURVIVAL EXPERIMENTS IN 3 NAÏVE ANIMALS.
Implant tension correlated with changes in annular
geometry (Figure 3), and the feasibility of coronary
artery protection was demonstrated (Online Figure 2),
although, in fact, no coronary compression was
observed in any of these experiments.
ANATOMIC SUITABILITY IN HUMANS. We reviewed
14 cardiac CT angiograms for anatomic suitability
from patients with an intracardiac shunt and a dilated
right heart. RAA morphology and anatomic position
were consistent across subjects. All 14 met both
suitability criteria for transatrial pericardial access.
Thirteen of 14 patients (93%) had a clearly deﬁned
atrioventricular groove. Of those, all had at least
1 epicardial coronary artery that crossed the projected
course of the TRAIPTA implant.DISCUSSION
To our knowledge, this is the ﬁrst description of a
transcatheter tricuspid valve repair and the ﬁrst
TABLE 1 MRI Findings (N ¼ 9)
Baseline Post-TRAIPTA
Follow-Up
(Mean 9.7 days)
Cardiac chambers
RA area, cm2 11.8  1.6 12.0  1.2 11.4  2.1
RV end-diastolic volume, ml 84.5  12.3 65.6  20.9 73.9  20.4
RV end-systolic volume, ml 42.5  14.8 35.8  16.9 36.8  17.8
RV stroke volume, ml 42.0  7.5 29.9  5.9* 37.1  6.5
RV ejection fraction, % 50.8  11.6 47.6  10.3 52.1  10.4
LA area, cm2 12.3  2.6 11.1  1.1 12.1  1.9
LV end-diastolic volume, ml 93.3  14.7 66.9  13.3* 79.2  8.7
LV end-systolic volume, ml 51.5  13.9 36.6  11.3* 41.9  5.6
LV stroke volume, ml 41.8  8.8 30.3  5.6* 37.3  8.0
LV ejection fraction, % 45.3  9.6 46.1  8.3 46.8  6.5
TV annulus‡
TV septal-lateral, mm 24.4  2.1 12.6  2.8† 13.9  3.1†
TV anteroposterior, mm 32.8  2.4 22.6  4.0† 22.6  3.6†
TV area, cm2 11.8  1.9 5.3  1.8† 4.4  1.5†
TV annular perimeter, cm 13.2  1.1 9.6  2.4† 9.8  1.2†
TV leaﬂet coaptation length, mm 3.1  0.9 6.8  0.8† 6.1  0.8†
MV annulus‡
MV septal-lateral, mm 29.2  3.7 24.8  3.8* 25.2  2.4
MV anteroposterior, mm 31.1  2.5 26.3  2.4* 26.1  3.3*
MV area, cm2 9.3  2.0 6.0  1.3† 5.6  1.2†
MV annular perimeter, cm 11.9  1.1 9.3  1.2† 9.1  0.9†
Pericardium
Pericardial effusion, ml 0.0  0.0 45.8  43.7† 0.0  0.0
Values are mean  SD. *p < 0.05. †p < 0.001 compared with baseline. ‡Annular measurements were performed
in mid-systole.
LA ¼ left atrium; LV ¼ left ventricle; MRI ¼magnetic resonance imaging; MV ¼mitral valve; RA ¼ right atrium;
RV ¼ right ventricle; TRAIPTA ¼ transatrial intrapericardial tricuspid annuloplasty; TV ¼ tricuspid valve.
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487mechanical intervention accomplished via a right
atrial exit to the pericardium. In contrast with the
mitral valve, where primary leaﬂet or subvalvular
apparatus pathology often contributes to regurgita-
tion, most symptomatic TR is caused by annular
dilation with intact valvular apparatus. For this
reason, annuloplasty is the preferred surgical repair.
We showed a dose-response relationship between
TRAIPTA tension and tricuspid geometry and leaﬂet
coaptation; we showed that TRAIPTA treats func-
tional TR in a clinically relevant animal model, that
the right atrial exit port is reliably closed, that the
procedure is rapid and reproducible, and that eligible
humans appear to have suitable anatomy.
TRANSATRIAL PERICARDIAL ACCESS. Transatrial
pericardial access was ﬁrst described by Verrier et al.
(14) to sample pericardial ﬂuid, drain effusions, and
deliver drugs. A number of interventional (15) and
electrophysiology procedures require pericardial
access, which is usually obtained through a “dry”
subxiphoid puncture and which risks hemoper-
icardium from right ventricular or coronary artery
laceration.
TRAIPTA is the ﬁrst mechanical intervention per-
formed by exiting the heart from within via a trans-
atrial puncture. This approach provides direct access
to the base of the heart in the plane of the atrioven-
tricular groove. The puncture was sealed with off-
the-shelf nitinol closure devices, and hemostasis
was consistently achieved in all animals. However,
right atrial pressures were low in these animals, and
the risk of bleeding could be higher in patients with
severe TR or coagulopathy. Small post-procedural
pericardial effusions were observed but without
tamponade, whereas in patients, a temporary peri-
cardial drain would likely be placed. Complete reso-
lution of these effusions was observed in all animals
at follow-up, even with the permanent TRAIPTA
implant in situ. Our current technique requires
inversion of the appendage to ensure proper nitinol
closure device positioning. We believe that the device
redistributes force adequately to protect against
appendage injury.
INTRAPERICARDIAL TRICUSPID ANNULOPLASTY.
Aortic and mitral valve disease commonly coexist
with tricuspid valve disease. Despite the adoption of
transcatheter aortic and mitral valve interventions,
there remains an unmet need for transcatheter
tricuspid valve repair (16), particularly because un-
treated TR after aortic or mitral surgery confers a poor
outcome. Percutaneous orthotopic (17,18) or hetero-
topic (19,20) prosthetic tricuspid valve replacementhas been described, but these risk thrombosis with-
out anticoagulation. TRAIPTA would not require
anticoagulation because the implant is extravascular,
although some patients may have other indica-
tions (e.g., atrial ﬁbrillation). Transcatheter tricuspid
replacement valves are contraindicated in the pres-
ence of transvenous pacing or deﬁbrillator leads, but
TRAIPTA is possible because it is extravascular.
Transatrial exit is possible in the presence of right
atrial pacing leads because the puncture can be per-
formed distant to the lead insertion point. TRIAPTA
may also be a treatment strategy for pediatric and
adult congenital systemic single right ventricle
patients with TR.
In this study, we correlated implant tension
with reduction in tricuspid annular dimensions,
especially in the septal-lateral dimension, which is
the main axis of annular dilation (7) and the principal
target for surgical annuloplasty. The magnitude of
geometric modiﬁcation easily exceeded ranges re-
ported for surgical annuloplasty (21). We observed
lesser geometric modiﬁcation of the mitral annulus,
likely reﬂecting the higher pressures and increased
myocardial thickness of the left heart. Nevertheless,
FIGURE 3 Geometric Change Resulting From Annuloplasty
(A) Mean tricuspid valve annular dimensions in 5- and 2-chamber MRI views. (B) Mean mitral valve annular dimensions in 4- and 2-chamber
magnetic resonance imaging views. Arrows denote measured annular dimensions (A and B). (C) The transatrial intrapericardial tricuspid
annuloplasty (TRAIPTA) implant was tensioned using a force meter attached to the suture. *p < 0.05; **p < 0.001.
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488this technique could potentially be adapted to treat
both atrioventricular valves. Unlike surgery, TRAIPTA
can be performed in the beating heart and titrated in
real time under varying loading conditions imposed
by hemodynamic provocations such as exercise and
volume. Importantly, we found geometric change
was maintained over the follow-up period.
ANIMAL MODEL. TR has been induced in animals by
surgical annular disruption (22,23), but there are notranscatheter large animal models of functional TR.
In this study, we found that to create TR required
multiple insults, including volume and pressure
overload, as well as considerable time to allow the
right ventricle to remodel.
STUDY LIMITATIONS AND POTENTIAL FAILURE
MODES. TRAIPTA requires the pericardial space to
be free of adhesions, which could impede implant
delivery. This likely precludes TRAIPTA in
FIGURE 4 Imaging of Tricuspid Valve and Annulus Before and After Annuloplasty
(A) Magnetic resonance imaging 5-chamber view at baseline. Arrow denotes tricuspid annulus. (B) A 5-chamber view after transatrial intra-
pericardial tricuspid annuloplasty (TRAIPTA). (C) A 2-chamber view at baseline. (D) A 2-chamber view after TRAIPTA. (E) Tricuspid leaﬂet
coaptation at baseline. Arrow denotes coaptation length. (F) Tricuspid leaﬂet coaptation after TRAIPTA. Arrow denotes coaptation length.
(G) Intracardiac echocardiography of the tricuspid valve before deployment of the TRAIPTA implant. (H) Color Doppler shows a central jet
of moderate-severe tricuspid regurgitation (peak velocity 1.8 m/s). (I) Tensioned TRAIPTA implant at the level of the tricuspid annulus (arrow).
(J) Color Doppler showing signiﬁcant reduction in tricuspid regurgitation severity after TRAIPTA. Ao ¼ aorta; LA ¼ left atrium; LV ¼ left
ventricle; RA ¼ right atrium; RV ¼ right ventricle.
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489patients with previous pericardiotomy or pericarditis.
However, the technique might be useful in conjunc-
tion with transcatheter aortic valve replacement
and/or mitral valve repair. Because of its circumfer-
ential position around the heart, 1 potential com-
plication is coronary artery and coronary sinus
compression. At the level of tension exerted toachieve 40% reduction in the tricuspid septal-lateral
dimension, we did not observe any coronary artery
or sinus compression (Online Figure 2), albeit in ani-
mals without severe RV hypertension. To address this
potential complication, we demonstrated that a pro-
tection element could be incorporated into the
TRAIPTA implant (Online Figure 2) and that its
FIGURE 5 Necropsy
(A) Transatrial intrapericardial tricuspid annuloplasty (TRAIPTA)
implant at 48 days of follow-up endothelialized and fused to the
myocardium along the atrioventricular groove. (B) Right atrial
appendage (RAA) puncture site at 7 days of follow-up, sealed
with nitinol closure device. LAA ¼ left atrial appendage; LV ¼ left
ventricle.
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490position along the TRAIPTA implant was adjustable
interactively in situ. This bridgelike element, origi-
nally developed in our lab for mitral cerclage annu-
loplasty (12), directs compressive force away from an
entrapped coronary artery or sinus. Finally, in com-
mon with all permanent implants, potential failure
modes are implant migration and tissue erosion. We
did not observe any implant migration, and on nec-
ropsy, the TRAIPTA device was fully adhered to the
myocardium with no macroscopic evidence of tissue
erosion (Figure 5A). Similar macroscopic ﬁndings
were observed for the nitinol closure device at the
right atrial puncture site. No pericarditis or pericar-
dial adhesions were observed, perhaps because weadministered intrapericardial glucocorticoids after
deployment. These ﬁnding suggests a very low like-
lihood of late device migration or tissue erosion, but
this will be evaluated in a future long-term animal
study.
CLINICAL TRANSLATION AND SUITABILITY OF
HUMAN ANATOMY. RAA morphology was suitable
for transatrial pericardial access in all patients, and
most had a clearly deﬁned atrioventricular groove
suitable for TRAIPTA. Most patients also had epicar-
dial coronary arteries crossing the projected course
of the TRAIPTA implant, and we therefore anticipate
that protection elements would be required in human
implementation (Online Figure 2).
CONCLUSIONS
We report a novel transcatheter tricuspid annulo-
plasty technique using transatrial pericardial access
and pericardial deployment of a permanent implant.
We demonstrate interactive adjustment of tricuspid
annular and leaﬂet geometry in naïve swine, compa-
rable to that achieved with surgical annuloplasty.
In animals with functional tricuspid regurgitation,
this geometric adjustment reduces the severity of
regurgitation.
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